Prediction of response to trasutuzumab/pertuzumab/taxane therapy by microRNA in HER2 positive advanced breast cancer

被引：0
|
作者：
Kawachi, A. [1 ]
Shimomura, A. [1 ]
Matsuzaki, J. [2 ]
Kawauchi, J. [2 ]
Takizawa, S. [2 ]
Sakamoto, H. [3 ]
Shimizu, C. [1 ]
Tamura, K. [1 ]
Ochiya, T. [2 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr, Res Inst, Div Mol & Cellular Med, Tokyo, Japan
[3] Natl Canc Ctr, Res Inst, FIOC, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
123P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A pilot study of pertuzumab, trastuzumab and eribulin for patients with advanced HER2 positive breast cancer
    Ishihara, M.
    Tamaru, S.
    Oda, H.
    Yamashita, Y.
    Tono, Y.
    Mizuno, T.
    Katayama, N.
    CANCER RESEARCH, 2016, 76
  • [2] SAFETY OF TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED HER2 POSITIVE ADVANCED BREAST CANCER
    Sakaguchi, Haruna
    Ishihara, Mikiya
    Sawaki, Akihiko
    Nagaharu, Keiki
    Oda, Hiroyasu
    Sugawara, Yumiko
    Tamaru, Satoshi
    Yamashita, Yoshiki
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2014, 25
  • [3] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
  • [4] Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
    Bilici, Ahmet
    Olmez, Omer Fatih
    Sezer, Ahmet
    Oksuzoglu, Berna
    Kaplan, Muhammet Ali
    Karadurmus, Nuri
    Cubukcu, Erdem
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Erdem, Dilek
    Basaran, Gul
    Cakar, Burcu
    Seker, Mesut
    Arslan, Cagatay
    Goksu, Sema Sezgin
    Cicin, Irfan
    Gumus, Mahmut
    Selcukbiricik, Fatih
    Harputluoglu, Hakan
    Helvaci, Kaan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Analysis of biomarkers in a pilot study of pertuzumab, trastuzumab and eribulin for advanced HER2 positive breast cancer
    Tono, Yasutaka
    Ishihara, Mikiya
    Miyahara, Yoshihiro
    Ikeda, Hiroaki
    Shiku, Hiroshi
    Shiraishi, Taizo
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Eribulin should be a candidate strategy in combination with pertuzumab plus trastuzumab for taxane pretreated HER2 positive advance breast cancer
    Araki, K.
    Fukada, I.
    Kobayashi, K.
    Takahashi, S.
    Ito, Y.
    CANCER RESEARCH, 2017, 77
  • [7] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Prediction of response to neoadjuvant chemotherapy in HER2 positive breast cancer by MammaTyper®
    Scatena, C.
    Belcastro, E.
    Scarpitta, R.
    Naccarato, A. G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 30 - 30
  • [9] Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03
    Yamashita, Toshinari
    Kawaguchi, Hidetoshi
    Masuda, Norikazu
    Kitada, Masahiro
    Narui, Kazutaka
    Hattori, Masaya
    Yoshinami, Tetsuhiro
    Matsunami, Nobuki
    Yanagihara, Kazuhiro
    Nagashima, Takeshi
    Bando, Hiroko
    Yano, Hiroshi
    Hasegawa, Yoshie
    Nakamura, Rikiya
    Kashiwaba, Masahiro
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Prediction of HER2 positive breast cancer patients' response to anti-HER2 therapy using mRNA level
    Atallah, N.
    Makhlouf, S.
    Li, X. M.
    Zhangy, Y.
    Rakha, E.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 114 - 114
12345